Cite
HARVARD Citation
Riedel, R. et al. (2023). Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. European journal of cancer. pp. 124-135. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Riedel, R. et al. (2023). Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. European journal of cancer. pp. 124-135. [Online].